Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

CMS Should Broaden Coverage for Germline Mutation Testing

Lucy Langer, MD and Becky Clark, MS, CGC
Published: Wednesday, Jul 31, 2019
Lucy Langer, MD

Lucy Langer, MD

Over the past decade, tremendous progress has been made in the development of DNA sequencing technologies. Of particular use to the cancer community is next-generation sequencing (NGS), the newer technique of higher throughput evaluation of genetic sequences. Sometimes referred to as massively parallel sequencing, this advanced technology evaluates millions of DNA sequences simultaneously, representing a true revolution compared with traditional, labor-intensive methods in which far less DNA could be sequenced at once.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication